| 96361 | The provider administers intravenous, or IV, fluids with electrolytes through an already established intravenous route for each additional hour to treat more severe dehydration. | 9 | 140 | 3,200 | $160 | $1.1M |
| J2350 | Injection, ocrelizumab, 1 mg | 1 | 10 | 140 | $3,710 | $705.3K |
| 99283 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a low level of medical decision making. | 8 | 360 | 1,550 | $70 | $614.4K |
| 99284 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making. | 10 | 430 | 760 | $60 | $484.6K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 11 | 20 | 320 | $60 | $483K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 9 | 30 | 550 | $240 | $428.8K |
| 99282 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a straightforward level of medical decision making. | 16 | 190 | 1,790 | $90 | $390.9K |
| 96365 | The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease. | 18 | 140 | 2,200 | $90 | $358.4K |
| 99285 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a high level of medical decision making. | 16 | 330 | 1,350 | $60 | $338K |
| J2323 | Injection, natalizumab, 1 mg | 1 | 10 | 80 | $380 | $291.1K |